| scholarly article | Q13442814 |
| P356 | DOI | 10.4161/CBT.24342 |
| P953 | full work available at URL | http://www.tandfonline.com/doi/pdf/10.4161/cbt.24342 |
| https://doi.org/10.4161/cbt.24342 | ||
| https://europepmc.org/articles/PMC3813564 | ||
| https://europepmc.org/articles/PMC3813564?pdf=render | ||
| https://www.tandfonline.com/doi/pdf/10.4161/cbt.24342?needAccess=true | ||
| P932 | PMC publication ID | 3813564 |
| P698 | PubMed publication ID | 23760490 |
| P2093 | author name string | Mari Iida | |
| Neha Luthar | |||
| David A. Campbell | |||
| Anne M. Traynor | |||
| Deric L. Wheeler | |||
| Toni M. Brand | |||
| Megan M. Starr | |||
| P2860 | cites work | Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 |
| Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma | Q24561567 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors | Q27851678 | ||
| The phosphoinositide 3-kinase pathway | Q27860738 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| PI3K‐independent AKT activation in cancers: A treasure trove for novel therapeutics | Q28259003 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| EGF-ERBB signalling: towards the systems level | Q29619032 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Understanding resistance to EGFR inhibitors-impact on future treatment strategies | Q34088424 | ||
| Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice | Q34181861 | ||
| Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin | Q34388048 | ||
| Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study | Q34471062 | ||
| Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. | Q34554584 | ||
| Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab | Q35001415 | ||
| Akt inhibitors in clinical development for the treatment of cancer | Q35628576 | ||
| A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities | Q35701021 | ||
| Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. | Q37113071 | ||
| Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer | Q37168778 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| Cetuximab: from bench to bedside. | Q37678510 | ||
| Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway | Q37762205 | ||
| AKT signaling in physiology and disease | Q37765214 | ||
| MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo | Q38431323 | ||
| Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling | Q38500176 | ||
| Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma. | Q39355339 | ||
| MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis | Q39447204 | ||
| Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells | Q39612275 | ||
| Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. | Q39707372 | ||
| PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival | Q39987929 | ||
| Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members | Q40009294 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Structural basis for inhibition of the epidermal growth factor receptor by cetuximab | Q45345151 | ||
| Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck | Q46595210 | ||
| EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer | Q46662707 | ||
| Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. | Q46708758 | ||
| Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas | Q51214174 | ||
| Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. | Q54636490 | ||
| Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head | Q56688854 | ||
| Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage | Q80901395 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cetuximab | Q420296 |
| non-small-cell lung carcinoma | Q3658562 | ||
| MK-2206 | Q25100065 | ||
| allosteric inhibitor | Q70361704 | ||
| P304 | page(s) | 481-491 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab | |
| P478 | volume | 14 |
| Q36076364 | 5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells |
| Q52731012 | A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206. |
| Q38465098 | Allosteric therapies for lung cancer |
| Q38868047 | Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer |
| Q35754270 | Diverse involvement of isoforms and gene aberrations of Akt in human lung carcinomas |
| Q36036046 | Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines |
| Q92538857 | FOXO3 Transcription Factor Regulates IL-10 Expression in Mycobacteria-Infected Macrophages, Tuning Their Polarization and the Subsequent Adaptive Immune Response |
| Q36241312 | Litchi seed extract inhibits epidermal growth factor receptor signaling and growth of Two Non-small cell lung carcinoma cells |
| Q33906921 | Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective |
| Q46278768 | Overcoming resistance to cetuximab with honokiol, a small-molecule polyphenol |
| Q40075067 | PPAR-γ and Akt regulate GLUT1 and GLUT3 surface localization during Mycobacterium tuberculosis infection |
| Q36117718 | Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib |
| Q34387657 | Proteogenomic analysis of human chromosome 9-encoded genes from human samples and lung cancer tissues |
| Q35144924 | RNA interference targeting enhancer of polycomb1 exerts anti-tumor effects in lung cancer |
| Q42381878 | Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells. |
| Q36909843 | Squamous Cell Cancers: A Unified Perspective on Biology and Genetics |
| Q35129076 | Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy |
| Q89973548 | Targeting AKT/PKB to improve treatment outcomes for solid tumors |
| Q48187016 | Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins |
| Q97074390 | The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication |
| Q38199737 | Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer |
Search more.